Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial

Background: Despite high disease burden, systemic treatment options for patients with atopic hand and/ or foot dermatitis (H/F AD) are limited. Objectives: To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. Methods: In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. Results: A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab ( n = 67) or placebo ( n = 66). At week 16, significantly more patients receiving dupilumab ( n = 27) than placebo ( n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. Limitations: Short-term, 16 -week treatment period. Conclusion: Dupilumab monotherapy resulted in significant improvements across different domains of H/ F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.